Business Context and Reporting Period
This Form 8-K is filed by Reneo Pharmaceuticals, Inc. (trading symbol: RPHM) on November 13, 2023. The filing serves to announce the Company's financial results for the third quarter ended September 30, 2023, along with recent corporate updates. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The provided text is a cover page and index for the 8-K filing. It references a press release (Exhibit 99.1) containing the actual financial data but does not include the specific numerical values within this document.
- Revenue, Profit, and Margins: The filing text does not provide a clear value.
- Cash Flow and Liquidity: The filing text does not provide a clear value.
- Debt: The filing text does not provide a clear value.
Material Changes
The filing text does not provide a clear value regarding specific material changes versus the prior comparable period. It only indicates that such results were reported in the accompanying press release.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for specific guidance, outlook, management commentary, risks, or contingencies. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific Q3 2023 financial figures (revenue, net loss, cash position) in the attached Exhibit 99.1 Press Release, as they are not present in the 8-K cover text.
- Confirm the Company's status as an emerging growth company and its implications for financial reporting standards.
- Review the "furnished" status of the financial data to understand its legal standing regarding liability and incorporation by reference.
- Check for any updates on the Company's principal executive offices or contact information (listed as Irvine, California).